603858.SH
步长制药
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 15.18
−2.19%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 11.7B | 11.9B | 11.0B | 13.2B | 15.0B |
| Cost of Revenue | 4.3B | 4.4B | 4.4B | 4.2B | 4.2B |
| Gross Profit | 7.4B | 7.5B | 6.6B | 9.0B | 10.7B |
| Operating Expenses | |||||
| R&D Expense | 237.8M | 240.1M | 345.4M | 335.1M | 284.1M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 830.4M | 843.0M | 1.0B | 995.9M | 902.5M |
| Selling & Marketing Expense | 4.7B | 4.8B | 4.3B | 6.4B | 7.5B |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 6.0B | 6.2B | 6.0B | 8.0B | 9.0B |
| Cost and Expenses | 10.3B | 10.6B | 10.4B | 12.2B | 13.2B |
| Operating Income (EBIT) | 569.1M | 566.1M | (246.8M) | 436.0M | (1.2B) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 540.4M | 534.0M | (365.3M) | 394.6M | (1.3B) |
| Income Tax Expense | 334.9M | 341.7M | 337.1M | 242.7M | 331.6M |
| Bottom Line | |||||
| Net Income | 373.9M | 360.8M | (553.8M) | 319.0M | (1.5B) |
| Earnings from Cont. Ops | 205.5M | 192.3M | (702.4M) | 151.9M | (1.6B) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 373.9M | 360.8M | (553.8M) | 319.0M | (1.5B) |
| Per Share | |||||
| Basic EPS | CN¥0.35 | CN¥0.34 | (CN¥0.51) | CN¥0.29 | (CN¥1.38) |
| Diluted EPS | CN¥0.35 | CN¥0.34 | (CN¥0.51) | CN¥0.29 | (CN¥1.38) |
| Revenue Per Share | CN¥11.09 | CN¥11.24 | CN¥10.16 | CN¥11.98 | CN¥13.52 |
| Shares | |||||
| Basic Shares Outstanding | 1.1B | 1.1B | 1.1B | 1.1B | 1.1B |
| Diluted Shares Outstanding | 1.1B | 1.1B | 1.1B | 1.1B | 1.1B |
| Profitability Metrics | |||||
| EBITDA | — | 1.1B | 362.4M | 1.0B | (761.4M) |
| D&A | — | 509.5M | 609.1M | 583.3M | 488.0M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026